03 Profile
Vital Signsby Bridgehead
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Long Covid
James Chalmers: no photograph is held, so the academic plate is shown instead.
Academic
James Chalmers
M.D., Ph.D., Rhodes Chair of Experimental Therapeutics and Clinical Pharmacology at the University of Oxford
1
1
0
2
0
July 2026Aug 2026Sept 2026Oct 2026Nov 2026to date
4
press citations on 2 topics since 23 Jul 2026 · last quoted 11 Oct 2026
02 Quoted on · 2 of 29 topics
James Chalmers: key facts
- Kind of voice
- Academic
- Role
- M.D., Ph.D., Rhodes Chair of Experimental Therapeutics and Clinical Pharmacology at the University of Oxford
- Quoted on
- Long Covid, Respiratory (asthma/COPD)
- Tracked press citations
- 4
- Most recently quoted
- 11 Oct 2026
- First quoted
- 23 Jul 2026
04 The signal · where James Chalmers sits on long covid
Ranked 21= of 100 voices quoted in the press on long covid, level with 21 others on 2 citations.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- Respiratory (asthma/COPD)23= of 100
- 1=
Dr Charles ShepherdClinicianTrustee and Honorary Medical Adviser, The ME Association9 - 1=Professor Dmitry PshezhetskiyAcademicProfessorial Research Fellow, Norwich Medical School, University of East Anglia9
- 3
Dr. Ewan HunterBusiness leaderChief Data Officer, Oxford BioDynamics Plc6 - 21=
Dr Tom DolphinUnionChair of Council, British Medical Association (BMA)2 - 21=Professor Emma WallAcademicprofessor of infectious diseases at Queen Mary University of London2
- 21=James ChalmersAcademicM.D., Ph.D., Rhodes Chair of Experimental Therapeutics and Clinical Pharmacology at the University of Oxford2
- 21=David PutrinoAcademicPhD, director of rehabilitation innovation at the Mount Sinai Health System in New York City2
- 21=William "Skip" PridgenAcademicM.D., Co-Founder and Chief Executive Officer of PridCor Therapeutics2
Showing the leaders and the ranks around 21=, of 100 voices · See every voice on the topic →
05 On the record · press
What James Chalmers has said
By outlet · linked articles
- generalatlantic.com1
- insideprecisionmedicine.com1
- medicalxpress.com1
- respiratory-therapy.com1
Where James Chalmers has been quoted
- 01Lung and Mouth Bacteria Linked to Long COVID Severity and Symptomsinsideprecisionmedicine.com · 11 Oct 2026
- 02Very severe long COVID linked to differences in lung and mouth microbiomesmedicalxpress.com · 11 Oct 2026
- 03Expedition Therapeutics Announces Oversubscribed $115 Million Series B Financing to Advance Next-Generation DPP1 Inhibitor for COPDgeneralatlantic.com · 5 Aug 2026
- 04ProAxsis Transitions to Independent Growth Company to Advance Respiratory Researchrespiratory-therapy.com · 23 Jul 2026
Verbatim
“People who had the worst symptoms five to six months after COVID infection had big changes in the microbiome in their mouth and lungs.”
“We urgently need to know what causes long COVID because it remains a major health care problem. Understanding what causes it could lead to better treatments; the microbiome can be changed using antibiotics, probiotics or other measures.”
“COPD remains one of the leading causes of death worldwide, yet current therapies primarily manage symptoms and do not adequately address the chronic neutrophilic inflammation that drives disease progression and exacerbations. By selectively targeting DPP1, this investigational therapy has the potential to interrupt a key upstream inflammatory pathway, offering a novel approach that could improve outcomes for patients.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 10 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.